Business · 05/12/2023Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Genzyme Corporation for Rare Pediatric Disease Product XENPOZYME
Summary
The FDA has issued a priority review voucher to Genzyme Corporation for its rare pediatric disease product XENPOZYME, following a review of the product's eligibility under the Federal Food, Drug, and Cosmetic Act.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →